# A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults

> **NCT05572879** · PHASE3 · COMPLETED · sponsor: **EuBiologics Co.,Ltd** · enrollment: 2600 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** EuCorVac-19
- **BIOLOGICAL:** ChAdOx1 nCoV-19

## Key facts

- **NCT ID:** NCT05572879
- **Lead sponsor:** EuBiologics Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-01
- **Primary completion:** 2023-06-23
- **Final completion:** 2024-02-09
- **Target enrollment:** 2600 (ACTUAL)
- **Last updated:** 2024-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05572879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05572879, "A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05572879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*